Literature DB >> 31036566

EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival.

Zachary R Gallegos1, Patrick Taus1, Zane A Gibbs1, Kathleen McGlynn1, Nicholas C Gomez2,3, Ian Davis2,3,4, Angelique W Whitehurst5.   

Abstract

Ewing sarcoma is characterized by a pathognomonic chromosomal translocation that generates the EWSR1-FLI1 chimeric transcription factor. The transcriptional targets of EWSR1-FLI1 that are essential for tumorigenicity are incompletely defined. Here, we found that EWSR1-FLI1 modulates the expression of cancer/testis (CT) antigen genes, whose expression is biased to the testes but is also activated in cancer. Among these CT antigens, fetal and adult testis expressed 1 (FATE1) is most robustly induced. EWSR1-FLI1 associates with the GGAA repeats in the proximal promoter of FATE1, which exhibits accessible chromatin exclusively in mesenchymal progenitor cells (MPCs) and Ewing sarcoma cells. Expression of EWSR1-FLI1 in non-Ewing sarcoma cells and in MPCs enhances FATE1 mRNA and protein expression. Conversely, depletion of EWSR1-FLI1 in Ewing sarcoma cells leads to a loss of FATE1 expression. Importantly, we found that FATE1 is required for survival and anchorage-independent growth in Ewing sarcoma cells via attenuating the accumulation of BNIP3L, a BH3-only protein that is toxic when stabilized. This action appears to be mediated by the E3 ligase RNF183. We propose that engaging FATE1 function can permit the bypass of cell death mechanisms that would otherwise inhibit tumor progression.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  BNIP3L; CT antigen; EWSR1-FLI1; Ewing sarcoma; FATE1; RNF183; cancer/testis antigen

Mesh:

Substances:

Year:  2019        PMID: 31036566      PMCID: PMC6597881          DOI: 10.1128/MCB.00138-19

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  54 in total

1.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.

Authors:  O Delattre; J Zucman; B Plougastel; C Desmaze; T Melot; M Peter; H Kovar; I Joubert; P de Jong; G Rouleau
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

2.  NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.

Authors:  Michelle Kinsey; Richard Smith; Stephen L Lessnick
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

3.  Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation.

Authors:  Angelique W Whitehurst; Yang Xie; Scott C Purinton; Kathryn M Cappell; Jackie T Swanik; Brittany Larson; Luc Girard; John O Schorge; Michael A White
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

4.  The genomic landscape of pediatric Ewing sarcoma.

Authors:  Brian D Crompton; Chip Stewart; Amaro Taylor-Weiner; Gabriela Alexe; Kyle C Kurek; Monica L Calicchio; Adam Kiezun; Scott L Carter; Sachet A Shukla; Swapnil S Mehta; Aaron R Thorner; Carmen de Torres; Cinzia Lavarino; Mariona Suñol; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Michael S Lawrence; Petar Stojanov; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Sara Seepo; Brendan Blumenstiel; Matthew DeFelice; Ivan Imaz-Rosshandler; Angela Schwarz-Cruz Y Celis; Miguel N Rivera; Carlos Rodriguez-Galindo; Mark D Fleming; Todd R Golub; Gad Getz; Jaume Mora; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2014-09-03       Impact factor: 39.397

5.  EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.

Authors:  Nicolò Riggi; Mario-Luca Suvà; Domizio Suvà; Luisa Cironi; Paolo Provero; Stéphane Tercier; Jean-Marc Joseph; Jean-Christophe Stehle; Karine Baumer; Vincent Kindler; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.

Authors:  R A Bailly; R Bosselut; J Zucman; F Cormier; O Delattre; M Roussel; G Thomas; J Ghysdael
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

7.  Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene.

Authors:  C De Smet; S J Courtois; I Faraoni; C Lurquin; J P Szikora; O De Backer; T Boon
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours.

Authors:  A A Jungbluth; E Stockert; Y T Chen; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; K J Busam; L J Old
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

9.  CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens.

Authors:  Luiz Gonzaga Almeida; Noboru J Sakabe; Alice R deOliveira; Maria Cristina C Silva; Alex S Mundstein; Tzeela Cohen; Yao-Tseng Chen; Ramon Chua; Sita Gurung; Sacha Gnjatic; Achim A Jungbluth; Otávia L Caballero; Amos Bairoch; Eva Kiesler; Sarah L White; Andrew J G Simpson; Lloyd J Old; Anamaria A Camargo; Ana Tereza R Vasconcelos
Journal:  Nucleic Acids Res       Date:  2008-10-05       Impact factor: 16.971

10.  Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer.

Authors:  Kimberly E Maxfield; Patrick J Taus; Kathleen Corcoran; Joshua Wooten; Jennifer Macion; Yunyun Zhou; Mark Borromeo; Rahul K Kollipara; Jingsheng Yan; Yang Xie; Xian-Jin Xie; Angelique W Whitehurst
Journal:  Nat Commun       Date:  2015-11-16       Impact factor: 14.919

View more
  7 in total

1.  Knockdown of RNF183 suppressed proliferation of lung adenocarcinoma cells via inactivating the STAT3 signaling pathway.

Authors:  Guangbin Ye; Hongcheng Luo; Tingting Zhang; Tianshu Lan; Bo Ling; Zhongquan Qi
Journal:  Cell Cycle       Date:  2022-02-01       Impact factor: 5.173

Review 2.  Role of immunotherapy in Ewing sarcoma.

Authors:  Erin Morales; Michael Olson; Fiorella Iglesias; Saurabh Dahiya; Tim Luetkens; Djordje Atanackovic
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 3.  BNIP3L/NIX-mediated mitophagy: molecular mechanisms and implications for human disease.

Authors:  Yue Li; Wanqing Zheng; Yangyang Lu; Yanrong Zheng; Ling Pan; Xiaoli Wu; Yang Yuan; Zhe Shen; Shijia Ma; Xingxian Zhang; Jiaying Wu; Zhong Chen; Xiangnan Zhang
Journal:  Cell Death Dis       Date:  2021-12-20       Impact factor: 8.469

Review 4.  The Role of Tissue-Specific Ubiquitin Ligases, RNF183, RNF186, RNF182 and RNF152, in Disease and Biological Function.

Authors:  Takumi Okamoto; Kazunori Imaizumi; Masayuki Kaneko
Journal:  Int J Mol Sci       Date:  2020-05-30       Impact factor: 5.923

5.  The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGFβ signaling in triple-negative breast cancer.

Authors:  Zane A Gibbs; Luis C Reza; Chun-Chun Cheng; Jill M Westcott; Kathleen McGlynn; Angelique W Whitehurst
Journal:  Elife       Date:  2020-06-09       Impact factor: 8.140

6.  Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC.

Authors:  Mabrouka Doghman-Bouguerra; Pascal Finetti; Nelly Durand; Ivy Zortéa S Parise; Silviu Sbiera; Giulia Cantini; Letizia Canu; Ségolène Hescot; Mirna M O Figueiredo; Heloisa Komechen; Iuliu Sbiera; Gabriella Nesi; Angelo Paci; Abir Al Ghuzlan; Daniel Birnbaum; Eric Baudin; Michaela Luconi; Martin Fassnacht; Bonald C Figueiredo; François Bertucci; Enzo Lalli
Journal:  Cancers (Basel)       Date:  2020-03-14       Impact factor: 6.639

7.  Sperm-specific COX6B2 enhances oxidative phosphorylation, proliferation, and survival in human lung adenocarcinoma.

Authors:  Chun-Chun Cheng; Joshua Wooten; Zane A Gibbs; Kathleen McGlynn; Prashant Mishra; Angelique W Whitehurst
Journal:  Elife       Date:  2020-09-29       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.